ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Koselugo Approved in EU for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas
June 23, 2021AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) ... -
AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder
April 14, 2020AstraZeneca and Merck have secured approval from the US Food and Drug Administration (FDA) for Koselugo (selumetinib) . -
FDA approves AstraZeneca’s Koselugo to treat rare genetic disorder
April 14, 2020AstraZeneca and MSD (Merck) have received the US Food and Drug Administration (FDA) approval for Koselugo (selumetinib) to treat a rare genetic condition called neurofibromatosis type 1 (NF1).
Pharma Sources Insight January 2025
